Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid

Cancer Biology and Therapy

Volumn 13, Issue 14, 2012, Pages 1491-1500

  Misso, Gabriella ^a   Porru, Manuela ^b   Stoppacciaro, Antonella ^c   Castellano, Maria ^a   De Cicco, Federica ^b   Leonetti, Carlo ^b   Santini, Daniele ^d   Caraglia, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Acid 10.4161 cbt.22274; Angiogenesis; Anticancer; Breast cancer; Denosumab; HUVEC; RANKL; Zoledronic

Indexed keywords

DENOSUMAB; ZOLEDRONIC ACID;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DIPHOSPHONATES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RANK LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870679586     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22274     Document Type: Article

References (34)

1. Zometa (zoledronic acid) [package insert] (2011) Novartis Pharmaceuticals Corporation, East Hanover, NJ.
2. Xgeva (denosumab) [package insert] (2010) Amgen Inc., Thousand Oaks, CA.
3. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118:1192-201; PMID:21987386; http://dx.doi.org/10.1002/cncr.26313.
4. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188-94; PMID:20444845; http://dx.doi.org/10.1093/annonc/mdq217.
5. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, et al.; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with earlystage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9:840-9; PMID:18718815; http://dx.doi.org/10.1016/S1470-2045(08)70204-3.
6. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012; 12:40-8; PMID:22014381; http://dx.doi.org/10.1016/j.clbc.2011.08.002.
7. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875-82; PMID:18725648; http://dx.doi.org/10.1200/JCO.2008.16.3832.
8. Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 2010; 95:559-66; PMID:20022990; http://dx.doi.org/10. 1210/jc.2009-1366.
9. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47:683-9; PMID:21324674; http://dx.doi.org/10. 1016/j.ejca.2010.11.024.
10. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94:164-70; PMID:15217454; http://dx.doi.org/10.1111/j.1464-4096.2004.04831.x.
11. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62:6538-44; PMID:12438248.
12. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13:4482-6; PMID:17671133; http://dx.doi.org/10.1158/1078-0432.CCR-07-0551.
13. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-61; PMID:12183663; http://dx.doi.org/10. 1124/jpet.102.035295.
14. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, et al. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009; 9:791-800; PMID:20025567; http://dx.doi.org/10.2174/156800909789760285.
15. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010; 11:141-54; PMID:20001436; http://dx.doi.org/10.1517/ 14656560903485664.
16. Green JR. Bisphosphonates: preclinical review. Oncologist 2004; 9(Suppl 4):3-13; PMID:15459425; http://dx.doi.org/10.1634/theoncologist.9-90004-3.
17. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-93; PMID:12154351; http://dx.doi.org/10.1038/nrc867.
18. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009; 9:626-38; PMID:19508172; http://dx.doi.org/10.2174/156800909789057033.
19. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182:509-15, discussion 515-6; PMID:19524963; http://dx.doi.org/10.1016/j.juro.2009.04.023.
20. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564-71; PMID:19237632; http://dx.doi.org/10.1200/JCO.2008.19.2146.
21. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132-9; PMID:21060033; http://dx.doi.org/10.1200/JCO.2010.29. 7101.
22. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337- 42; PMID:12748652; http://dx.doi.org/10.1038/ nature01658.
23. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88(Suppl):2961-78; PMID:10898340; http://dx.doi.org/10.1002/1097-0142(20000615) 88:12+〈2961::AID-CNCR12〉3.0.CO;2-L.
24. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009; 12:35-46; PMID:19105036; http://dx.doi.org/10.1007/s10456-008-9127-z.
25. Min JK, Cho YL, Choi JH, Kim Y, Kim JH, Yu YS, et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 2007; 109:1495-502; PMID:17038532; http://dx.doi.org/10.1182/blood-2006-06-029298.
26. Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, et al. Vascular endothelial growth factor upregulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003; 278:39548-57; PMID:12893832; http://dx.doi.org/10.1074/jbc.M300539200.
27. Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, et al. EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003; 10:218-29; PMID:12700650; http://dx.doi.org/10. 1038/sj.cdd.4401131.
28. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24:182-95; PMID:19016581; http://dx.doi.org/10.1359/jbmr.081112.
29. Costa L, Harper P, Coleman RE, Lipton A. Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol 2011; 77(Suppl 1):S31-7; PMID:21353179; http://dx.doi.org/10.1016/S1040-8428(11)70006- 3.
30. Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest 2011; 29:533-41; PMID:21843051; http://dx.doi.org/10.3109/07357907.2011. 605413.
31. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34:453-75; PMID:18423992; http://dx.doi.org/10.1016/j.ctrv.2008.02.004.
32. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009; 41:721-9; PMID:19536731; http://dx.doi.org/10.1055/s-0029-1224109.
33. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, et al. Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Support Care Cancer 2008; 16:209-14; PMID:17701225; http://dx.doi.org/10.1007/s00520-007-0315-y.
34. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 2001; 84:1586-90; PMID:11401309; http://dx.doi.org/10.1054/bjoc.2001.1832.